The EMAs CHMP has issued a eceived a positive opinion for 2 TNF inhibitor biosimilars: Idacio (adalimumab) and Kromeya (adalimumab). For the treatment of select inflammatory and autoimmune disorders https://t.co/lz7EvtTcTB